Pembrolizumab as a promising treatment in patients with classic or endemic Kaposi’s sarcoma
1. Treatment with pembrolizumab yielded a best overall response rate of 71%. 2. Adverse events...
Read More
Oncology
Ribociclib in addition to letrozole increases overall survival compared to letrozole alone
1. Overall survival was longer in the group receiving ribociclib with letrozole as compared with...
Read More
Rucaparib compared to standard-of-care chemotherapy showed promising clinical and safe response to treat BRCA1 or BRCA2 mutated, relapsed ovarian carcinoma
1. The median progression-free survival was 7.4 months in the rucaparib group and 5.7 months in...
Read More
Ribociclib plus letrozole provides greater overall survival benefit advanced breast cancer
1. Ribociclib plus letrozole provides significant overall survival benefit as compared to...
Read More
Breast cancer overdiagnosis rates not as high as estimated previously
1. About 1 in 7 cases of screen-detected cancer is overdiagnosed in the US population. 2. The rate...
Read More
Postoperative treatment without radioiodine has noninferior outcomes following thyroidectomy
1. Patients with low-risk thyroid cancer undergoing thyroidectomy, who did not receive radioiodine...
Read More
Non-alcoholic fatty liver disease-related hepatocellular carcinoma (HCC) differ clinically compared to HCC due to other causes
1. Patients with NAFLD-related HCC have longer disease-free survival compared to those with HCC...
Read More
Hepatocellular Carcinoma: The Viral Hepatitis Pathways
Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death worldwide, and incidence...
Read More
Pertuzumab has clinical benefits in metastatic breast cancer but is not cost-effective
1. The incremental cost-effectiveness ratio of the pertuzumab group was $436,679 per QALY gained....
Read More
Biosimilar HD201 has equivalent efficacy to trastuzumab in the treatment of ERBB2-positive (HER2) breast cancer
1. Total pathological complete response was not significantly different between trastuzumab and...
Read More
Liver Cancer: Support for the 3rd Leading Cancer-Related Cause of Death
Liver cancer is the third-highest cause of cancer-related deaths worldwide, and incidence of...
Read More
Cancer-Associated Thrombosis: A Look at Racial Disparities
When compared with the general population, patients with cancer-associated thrombosis (CAT) have...
Read More
Stereotactic Ablative Radiotherapy for Early-Stage Non-Small Cell Lung Cancer: A Nomogram Predicting Overall Survival Benefit
For a study, the researchers sought to create and evaluate a nomogram that could predict overall...
Read More
Compared With Younger Patients, Octogenarians Have a Higher Quality Of Life After Lung Resection
For a study, the researchers sought to compare patients aged less than 80 to patients aged more...
Read More
Stereotactic Radiosurgery in Small Cell Lung Cancer Brain Metastases: Treatment Patterns
Whole-brain radiotherapy (WBRT) had been the standard of care for brain metastases (BMs) from...
Read More
In Elderly Patients With Stage III Non-Small Cell Lung Cancer, Concurrent vs Sequential Chemoradiotherapy Has a Better Outcome
Lung cancer was the most common cancer-related death in the world. Non-small cell lung cancer was...
Read More
In Thymic Epithelial Tumours and Small Cell Lung Cancer, Arginase Pathway Markers of Immune-Microenvironment
Arginase-1 and the adenosine pathway, which were major regulators of antitumor immunity, might...
Read More
Lung Cancer Risk Factors in an Underserved Safety-Net Screening Cohort
To identify patients for lung cancer screening, the USPSTF (the United States Preventive Services...
Read More
As a Surrogate For Tumour Tissue, Genetic Profiling of Cell-Free DNA From Pleural Effusion in Advanced Lung Cancer Revealed Additional Clinical Actionable Information.
In advanced lung cancer patients, pleural effusion (PE) was proven to be a promising source of...
Read More
Overall Survival Benefit of Adding Platinum-Based Chemotherapy to Pembrolizumab in Advanced NSCLC With PD-L1 Tumour Proportion Score of more than or equal to 50% Predicted by dNLR-Based Score
Pembrolizumab (P) was a common first-line therapeutic option for advanced non-small cell lung...
Read More